|
|
Drug Delivery Technologies Revolutionizing Cardiovascular TherapiesPublished by: PharmaVision Published: Apr. 7, 2007 - 109 Pages Table of Contents
Abstract“The ability to deliver therapeutics sitespecifically, safely and efficiently remains a major challenge for the treatment of cardiovascular diseases. Additional drug delivery hurdles will need to be overcome as pharma companies and medical device manufacturers target specific areas of the vasculature. These advances will help to develop a new generation of medicines and devices to tackle the world’s leading killer.”Dr Cheryl Barton Cardiovascular disease (CVD) is the leading cause of death in the world, killing almost 17 million people each year. Types of CVD include coronary heart disease, hypertension, dyslipidemia and stroke - stroke is now the third leading cause of death, and the leading cause of disability in the western world (source: American Heart Association, AHA). Each year these conditions account for almost half of all deaths and are a tremendous financial burden on the healthcare system estimated to cost the US around US$560 billion annually (Source: Buxton, 2007). The development of drug delivery technology as we know it today was largely spawned from developments in the cardiovascular (CV) market. Oral controlled or sustainedrelease technologies such as OROS from ALZA, Elan’s chronotherapeutic oral drug absorption system (CODAS) and spheroidal oral drug absorption system (SODAS), the gastrointestinal therapeutic system (GITS) from Bayer, the wax-matrix system from Warner-Lambert and the TIMERx system from Penwest Pharma have helped to revolutionize the treatment of prevalent CV diseases. These delivery platforms have now become widely used in other therapy areas to aide patient compliance and optimize drug life-cycle management. Drug delivery specialists continue to adapt to market demands and the need to deliver therapeutics, site-specifically, safely and efficiently. They are achieving this through a variety of natural [affinity peptides and proteins, hemoglobin vesicle, monoclonal antibodies (mAbs)] and synthetic [polymers, liposomes, dendrimers] delivery technologies. However, the development of regenerative therapeutics which rely on the introduction of genetic material [DNA and siRNA] or cells [autologous and allogenic] into the host will raise their own delivery issues. In addition, the CV market has become increasingly reliant on the use of minimally invasive medical devices and significant advances in biocompatible and bioerodible materials continue to drive innovation within the market towards a new generation of devices. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||